Pfizer Partner 3SBio To Raise $400 Million In Stock Sale

3SBio, a Chinese partner of Pfizer, plans to raise approximately $400 million through a share placement, primarily for research and development. This follows a previous agreement in July where Pfizer invested $100 million in 3SBio, aiming to advance cancer medicines. The collaboration highlights continued U.S.-China ties in healthcare despite broader trade tensions, with 3SBio's shares soaring over 300% in the past year.